The Tubulin Inhibitor VERU-111 in Combination With Vemurafenib Provides an Effective Treatment of Vemurafenib-Resistant A375 Melanoma

Authors: Hongmei Cui, Qinghui Wang, Duane D. Miller, Wei Li

Source: Frontiers in Pharmacology, Vol 12 (2021)

Subject Terms: VERU-111, vemurafenib-resistance, melanoma, ERK, akt, skp2, Therapeutics. Pharmacology, RM1-950

File Description: electronic resource

Relation: https://www.frontiersin.org/articles/10.3389/fphar.2021.637098/full; https://doaj.org/toc/1663-9812

Access URL: https://doaj.org/article/6540032f3e5f49da9a6f0ad624f66370

Therapeutic efficacy of a novel βIII/βIV-tubulin inhibitor (VERU-111) in pancreatic cancer

Authors: Vivek K. Kashyap, Qinghui Wang, Saini Setua, Prashanth K. B. Nagesh, Neeraj Chauhan, Sonam Kumari, Pallabita Chowdhury, Duane D. Miller, Murali M. Yallapu, Wei Li, Meena Jaggi, Bilal Bin Hafeez, Subhash C. Chauhan

Source: Journal of Experimental & Clinical Cancer Research, Vol 38, Iss 1, Pp 1-14 (2019)

Subject Terms: VERU-111, Pancreatic cancer, β –tubulins, miR-200c, βIII/βIV-tubulin inhibitor, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

File Description: electronic resource

Relation: http://link.springer.com/article/10.1186/s13046-018-1009-7; https://doaj.org/toc/1756-9966

Access URL: https://doaj.org/article/7d607ed9963c4751b96e411a70836440

This result is not displayed to guests.
Login for full access.

FDA Reschedules Advisory Committee Meeting for COVID-19 Treatment

Authors: By:Formulary Watch

Source: Formulary Watch (USA), September 20, 2022 News, 2pp